MeSH term
Frequency | Condition_Probility | Animals | 112 | 0.0 |
Antigens, CD14/metabolism | 10 | 8.0 |
Biophysics | 2 | 4.0 |
CHO Cells | 24 | 1.0 |
Cytokines/biosynthesis | 4 | 0.0 |
Dose-Response Relationship, Drug | 14 | 0.0 |
*Drosophila Proteins | 9 | 0.0 |
Glucosamine/chemistry | 2 | 66.0 |
Hamsters | 24 | 0.0 |
Humans | 247 | 0.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
Membrane Glycoproteins/metabolism | 4 | 0.0 |
Models, Biological | 7 | 0.0 |
Models, Chemical | 2 | 0.0 |
Protein Conformation | 3 | 0.0 |
Receptors, Cell Surface/metabolism | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 146 | 0.0 |
Spectroscopy, Fourier Transform Infrared | 5 | 10.0 |
Temperature | 5 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 13 | 1.0 |
X-Ray Diffraction | 4 | 4.0 |
*Acute-Phase Proteins | 115 | 60.0 |
Blood | 6 | 3.0 |
Carrier Proteins/metabolism | 10 | 1.0 |
Cell Line | 27 | 0.0 |
Female | 54 | 0.0 |
*Membrane Glycoproteins | 149 | 16.0 |
Mice | 32 | 0.0 |
Pregnancy | 4 | 0.0 |
Rats | 8 | 0.0 |
Amino Acid Sequence | 28 | 0.0 |
Base Sequence | 24 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Cloning, Molecular | 10 | 0.0 |
Lipopolysaccharides/pharmacology | 9 | 0.0 |
*Membrane Proteins | 27 | 2.0 |
Molecular Sequence Data | 43 | 0.0 |
Binding Sites | 11 | 0.0 |
Lipopolysaccharides/antagonists & inhibitors/*metabolism | 5 | 62.0 |
Adult | 46 | 0.0 |
Carrier Proteins/*blood | 27 | 11.0 |
English Abstract | 9 | 0.0 |
Male | 55 | 0.0 |
Middle Aged | 40 | 0.0 |
Acute-Phase Proteins/analysis | 5 | 13.0 |
Biological Markers/blood | 2 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Lipopolysaccharides/metabolism | 13 | 11.0 |
Antigens, CD14/physiology | 3 | 8.0 |
Cells, Cultured/drug effects/metabolism | 2 | 4.0 |
*Gene Expression Regulation | 2 | 0.0 |
Mice, Inbred C3H | 5 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Mice, Knockout | 6 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 86 | 0.0 |
Laminin/*metabolism | 2 | 5.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Phosphorylation | 4 | 0.0 |
Acute-Phase Reaction/blood | 3 | 16.0 |
Antigens, CD14/*blood | 4 | 12.0 |
Biological Markers | 2 | 0.0 |
Cytokines/blood | 3 | 1.0 |
Infant, Newborn | 2 | 0.0 |
Solubility | 18 | 1.0 |
Cells, Cultured | 45 | 0.0 |
Comparative Study | 30 | 0.0 |
Cytokines/*biosynthesis | 3 | 0.0 |
In Vitro | 19 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
DNA, Bacterial | 2 | 6.0 |
Tumor Cells, Cultured | 15 | 0.0 |
Body Mass Index | 3 | 0.0 |
Inflammation/blood | 2 | 3.0 |
Tumor Necrosis Factor-alpha/*metabolism | 3 | 0.0 |
Acute-Phase Reaction | 4 | 8.0 |
Aged | 30 | 0.0 |
Flow Cytometry | 15 | 0.0 |
Fluorescein-5-isothiocyanate | 5 | 3.0 |
Fluorescent Dyes | 2 | 0.0 |
Lipopolysaccharides/metabolism/*pharmacology | 5 | 20.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Sepsis/*blood | 2 | 10.0 |
Shock, Septic/*blood | 3 | 15.0 |
Tumor Necrosis Factor-alpha/secretion | 5 | 4.0 |
Acute-Phase Proteins/*metabolism | 6 | 10.0 |
Carrier Proteins/*metabolism | 20 | 2.0 |
Cytokines/metabolism | 3 | 0.0 |
Neutrophils/immunology/metabolism | 2 | 10.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 21 | 0.0 |
Antigens, CD14/isolation & purification | 2 | 40.0 |
Interleukin-8/biosynthesis | 5 | 4.0 |
NF-kappa B/metabolism | 8 | 1.0 |
Signal Transduction | 7 | 0.0 |
Endotoxins/*metabolism | 4 | 18.0 |
Gram-Negative Bacteria/*metabolism | 4 | 44.0 |
Monocytes/metabolism | 8 | 2.0 |
Phospholipids/metabolism | 3 | 1.0 |
APACHE | 3 | 5.0 |
Acute-Phase Proteins/*analysis | 8 | 10.0 |
C-Reactive Protein/analysis | 6 | 1.0 |
Calcitonin/blood | 3 | 10.0 |
Interleukin-6/blood | 7 | 1.0 |
Protein Precursors/blood | 3 | 8.0 |
Carrier Proteins/metabolism/*physiology | 3 | 8.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Neutralization Tests | 2 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 13 | 2.0 |
Limulus Test | 5 | 21.0 |
Liposomes/chemistry/metabolism | 2 | 15.0 |
Mutation | 5 | 0.0 |
Polymyxin B/pharmacology | 4 | 7.0 |
Protein Structure, Secondary | 3 | 0.0 |
Antigens, CD14/*metabolism | 10 | 11.0 |
Biological Transport | 5 | 0.0 |
Transfection | 14 | 0.0 |
Carbohydrate Sequence | 4 | 1.0 |
Signal Transduction/immunology | 2 | 0.0 |
Acute-Phase Proteins/*pharmacology | 2 | 50.0 |
Carrier Proteins/*pharmacology | 4 | 8.0 |
Protein Binding | 18 | 0.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
Chronic Disease | 4 | 0.0 |
Receptors, Tumor Necrosis Factor/analysis | 2 | 3.0 |
Receptors, Tumor Necrosis Factor, Type I | 2 | 0.0 |
Receptors, Tumor Necrosis Factor, Type II | 2 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Molecular Weight | 6 | 0.0 |
Protein Binding/drug effects | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Time Factors | 15 | 0.0 |
U937 Cells | 4 | 0.0 |
Membrane Glycoproteins/genetics/immunology | 2 | 9.0 |
Blood Proteins/*genetics | 4 | 2.0 |
Carrier Proteins/*genetics | 7 | 0.0 |
Case-Control Studies | 7 | 0.0 |
Incidence | 2 | 0.0 |
Survival Analysis | 3 | 0.0 |
Antigens, CD14/*physiology | 12 | 25.0 |
Carrier Proteins/*physiology | 13 | 6.0 |
Cohort Studies | 4 | 0.0 |
Interleukin-6/metabolism | 5 | 2.0 |
Lipopolysaccharides/chemistry/*metabolism | 2 | 28.0 |
Analysis of Variance | 2 | 0.0 |
Antigens, CD14/biosynthesis | 3 | 4.0 |
Lipopolysaccharides/*metabolism | 29 | 23.0 |
Mitogen-Activated Protein Kinase 8 | 2 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Monocytes/*metabolism | 14 | 3.0 |
p38 Mitogen-Activated Protein Kinases | 3 | 0.0 |
Acylation | 2 | 2.0 |
Immunity, Natural | 4 | 1.0 |
*Glycoproteins | 4 | 0.0 |
*Phospholipid Transfer Proteins | 5 | 3.0 |
Adolescent | 13 | 0.0 |
Air Pollutants, Environmental/*toxicity | 2 | 16.0 |
Endotoxins/*toxicity | 3 | 14.0 |
Enzyme-Linked Immunosorbent Assay | 10 | 0.0 |
Questionnaires | 2 | 0.0 |
Prognosis | 6 | 0.0 |
Carrier Proteins/blood/*metabolism | 2 | 9.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Immunoblotting | 4 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
Lipoproteins, HDL/metabolism | 4 | 3.0 |
Promoter Regions (Genetics) | 6 | 0.0 |
Structure-Activity Relationship | 5 | 0.0 |
Electrostatics | 2 | 1.0 |
Lipoproteins, HDL/*metabolism | 3 | 2.0 |
Models, Molecular | 5 | 0.0 |
Phospholipids/*metabolism | 4 | 3.0 |
Recombinant Proteins/metabolism | 9 | 0.0 |
Sequence Alignment | 8 | 0.0 |
Blood Proteins/genetics/*metabolism | 2 | 11.0 |
Carrier Proteins/genetics/*metabolism | 5 | 1.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Clinical Trials | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Antigens, CD14/genetics/*metabolism | 5 | 27.0 |
Astrocytoma | 3 | 8.0 |
Lipopolysaccharides/*pharmacology | 19 | 4.0 |
Antigens, CD14/analysis | 2 | 1.0 |
Blood Proteins/*metabolism | 5 | 2.0 |
Carrier Proteins/analysis | 2 | 2.0 |
Chemiluminescent Measurements | 3 | 1.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Membrane Glycoproteins/*physiology | 3 | 1.0 |
Monocytes/immunology/metabolism | 3 | 6.0 |
Nitric Oxide/biosynthesis | 2 | 2.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
Interleukin-10/blood | 2 | 2.0 |
Blood Proteins/*pharmacology | 3 | 7.0 |
Carrier Proteins/blood | 4 | 3.0 |
Monocytes/immunology | 3 | 0.0 |
Child | 6 | 0.0 |
Child, Preschool | 5 | 0.0 |
Infant | 6 | 0.0 |
Neutrophil Activation | 3 | 6.0 |
Prospective Studies | 8 | 0.0 |
Survival Rate | 3 | 0.0 |
Viral Envelope Proteins/metabolism | 2 | 3.0 |
Endotoxins/*blood | 2 | 5.0 |
Interleukin-8/blood | 2 | 2.0 |
Leukocyte Count | 2 | 0.0 |
Neutrophils | 3 | 4.0 |
Tumor Necrosis Factor-alpha/analysis | 4 | 0.0 |
Acute-Phase Proteins/*biosynthesis | 2 | 9.0 |
Escherichia coli | 7 | 1.0 |
Salmonella/chemistry | 3 | 75.0 |
Carrier Proteins/genetics/*physiology | 2 | 2.0 |
Disease Models, Animal | 2 | 0.0 |
Phagocytosis/*physiology | 2 | 4.0 |
Cytokines/*metabolism | 3 | 1.0 |
Acute Disease | 4 | 0.0 |
C-Reactive Protein/metabolism | 4 | 1.0 |
Sepsis Syndrome/*blood | 2 | 22.0 |
Severity of Illness Index | 2 | 0.0 |
Kinetics | 19 | 0.0 |
Lipopolysaccharides/blood | 2 | 9.0 |
Antibodies, Blocking/pharmacology | 2 | 2.0 |
Cell Membrane/immunology/metabolism | 3 | 2.0 |
Fluorescence Resonance Energy Transfer | 3 | 6.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/biosynthesis | 3 | 13.0 |
Escherichia coli/*physiology | 2 | 22.0 |
Interleukin-6/secretion | 2 | 3.0 |
Lipopolysaccharides/*blood | 3 | 30.0 |
Acute-Phase Proteins/metabolism | 7 | 10.0 |
Interleukin-1/metabolism | 4 | 1.0 |
Carrier Proteins/*analysis | 5 | 6.0 |
Cytokines/pharmacology | 2 | 0.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Endotoxins/pharmacology | 3 | 4.0 |
Escherichia coli/immunology | 4 | 5.0 |
Cytokines/*secretion | 2 | 3.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Carrier Proteins/*immunology | 3 | 6.0 |
Cattle | 10 | 0.0 |
Chromatography | 2 | 1.0 |
Lipopolysaccharides | 3 | 2.0 |
Carrier Proteins/chemistry/*metabolism | 2 | 2.0 |
Antigens, CD14/*immunology | 4 | 8.0 |
Lipopolysaccharides/*immunology | 3 | 4.0 |
Phagocytosis | 2 | 0.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
Interleukin-6/biosynthesis | 4 | 1.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
Radioligand Assay | 2 | 0.0 |
Cell Adhesion Molecules/blood | 2 | 6.0 |
Lipoproteins, LDL/*blood | 2 | 1.0 |
Carrier Proteins/physiology | 4 | 3.0 |
Cell Adhesion/immunology | 2 | 1.0 |
Fluorescein-5-isothiocyanate/metabolism | 3 | 15.0 |
Neutrophils/*immunology | 2 | 1.0 |
Protein Binding/immunology | 3 | 1.0 |
Receptors, Immunologic/metabolism | 3 | 1.0 |
Carrier Proteins/pharmacology | 7 | 10.0 |
Cell Survival/drug effects | 5 | 0.0 |
Staphylococcus aureus/chemistry | 2 | 50.0 |
Blood Bactericidal Activity | 3 | 3.0 |
Permeability/drug effects | 2 | 8.0 |
Antigens, CD/blood | 3 | 1.0 |
Blood Proteins/*analysis | 4 | 2.0 |
Liver/metabolism | 3 | 0.0 |
Blood Proteins/pharmacology | 3 | 6.0 |
Neutrophils/immunology | 3 | 1.0 |
*Energy Metabolism | 3 | 3.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Macrophage Activation/*drug effects | 4 | 11.0 |
Antibodies/pharmacology | 5 | 1.0 |
Antigens, CD14/immunology | 2 | 3.0 |
Enzyme Activation/immunology | 2 | 1.0 |
DNA, Complementary | 2 | 0.0 |
Rabbits | 16 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
*Escherichia coli | 2 | 5.0 |
Intercellular Adhesion Molecule-1/metabolism | 2 | 1.0 |
Monocytes/drug effects/metabolism | 2 | 2.0 |
Binding, Competitive | 7 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Blotting, Western | 3 | 0.0 |
Interleukin-1/pharmacology | 4 | 0.0 |
Swine | 2 | 0.0 |
Protein Binding/physiology | 2 | 0.0 |
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects | 2 | 5.0 |
Lipid A/*analogs & derivatives/pharmacology | 2 | 10.0 |
Macromolecular Substances | 3 | 0.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Umbilical Veins/cytology | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Leukocytes, Mononuclear/drug effects/metabolism | 3 | 5.0 |
Lipid A/chemistry | 3 | 50.0 |
Phase Transition | 2 | 12.0 |
Sensitivity and Specificity | 4 | 0.0 |
Lipid A/analogs & derivatives | 2 | 66.0 |
Macrophages/immunology | 2 | 0.0 |
NF-kappa B/drug effects/metabolism | 2 | 8.0 |
Endotoxins/*pharmacology | 3 | 3.0 |
Gene Expression/drug effects | 2 | 0.0 |
Lipopolysaccharides/*toxicity | 4 | 7.0 |
Carrier Proteins/biosynthesis/*genetics | 2 | 4.0 |
Interleukin-6/pharmacology | 3 | 1.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Interleukin-4/metabolism | 2 | 2.0 |
Liver/*metabolism | 2 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
*Blood Bactericidal Activity | 4 | 8.0 |
Baculoviridae/genetics | 2 | 1.0 |
Lipopolysaccharides/*metabolism/pharmacology | 5 | 27.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Monocytes/physiology | 3 | 2.0 |
Chromatography, Ion Exchange | 4 | 1.0 |
Cricetulus | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Neutrophils/*drug effects/metabolism | 2 | 4.0 |
Respiratory Burst/*drug effects | 2 | 7.0 |
Body Composition | 2 | 0.0 |
Carrier Proteins/*genetics/metabolism | 2 | 0.0 |
Cytokines/*pharmacology | 4 | 1.0 |
Inflammation/physiopathology | 2 | 3.0 |
Complement 3a/analysis | 2 | 11.0 |
*Renal Dialysis | 2 | 0.0 |
Reference Values | 2 | 0.0 |
Lipopolysaccharides/blood/metabolism/*pharmacology | 2 | 66.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 4 | 1.0 |
Chromatography, Affinity | 2 | 0.0 |
Iron/metabolism | 2 | 1.0 |
Lactoferrin/*metabolism | 2 | 10.0 |
Monocytes/drug effects/*metabolism | 2 | 1.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 4 | 1.0 |
Antibodies/immunology | 2 | 0.0 |
Interleukin-1/biosynthesis | 2 | 1.0 |
Recombinant Proteins | 3 | 0.0 |
Antigens, CD/metabolism | 4 | 0.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Neutrophils/drug effects | 2 | 3.0 |
Acute-Phase Proteins/*physiology | 3 | 27.0 |
Lipopolysaccharides/*antagonists & inhibitors/metabolism | 2 | 66.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Osmolar Concentration | 2 | 0.0 |
Molecular Conformation | 3 | 1.0 |
Blood Proteins/*metabolism/pharmacology | 2 | 50.0 |
Creatinine/blood | 2 | 0.0 |
Radioimmunoassay | 2 | 0.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Stimulation, Chemical | 2 | 0.0 |
Neutrophils/*drug effects | 2 | 5.0 |
Superoxides/metabolism | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Lipopolysaccharides/*antagonists & inhibitors | 3 | 25.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Biological Markers/analysis | 2 | 0.0 |
Antigens, CD/*physiology | 6 | 1.0 |
Antigens, CD14 | 39 | 13.0 |
Antigens, Differentiation, Myelomonocytic/*physiology | 6 | 19.0 |
Superoxides/*metabolism | 2 | 2.0 |
Antigens, CD/*metabolism | 5 | 0.0 |
Antigens, Differentiation, Myelomonocytic/*metabolism | 5 | 8.0 |
Salmonella | 5 | 20.0 |
Antigens, Differentiation, Myelomonocytic/metabolism | 3 | 1.0 |
Antigens, Differentiation, Myelomonocytic/metabolism/*physiology | 2 | 50.0 |
Antigens, CD/biosynthesis/*metabolism | 2 | 18.0 |
Antigens, Differentiation, Myelomonocytic/biosynthesis/*metabolism | 2 | 40.0 |
Lipopolysaccharides/*metabolism/*pharmacology | 2 | 50.0 |
*Signal Transduction | 2 | 0.0 |
Gene Expression | 5 | 0.0 |
Heat | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Lipopolysaccharides/*metabolism/toxicity | 3 | 75.0 |
Shock, Septic/prevention & control | 2 | 33.0 |
Shock, Septic/etiology | 2 | 14.0 |
*Neutrophils | 2 | 13.0 |
Permeability | 5 | 3.0 |
Lipopolysaccharides/immunology | 2 | 1.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Antigens, CD18 | 2 | 2.0 |
Antigens, CD/immunology/*physiology | 2 | 6.0 |
Antigens, Differentiation, Myelomonocytic/immunology/*physiology | 2 | 40.0 |
Lipid A/metabolism | 2 | 22.0 |
Antigens, CD/physiology | 2 | 0.0 |
Antigens, Differentiation, Myelomonocytic/physiology | 2 | 9.0 |
Lipid A/*metabolism | 2 | 50.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Umbilical Veins | 2 | 0.0 |
Blood Proteins/metabolism/*pharmacology | 2 | 40.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*secretion | 2 | 2.0 |
Endotoxins/*antagonists & inhibitors | 2 | 16.0 |
Lipopolysaccharides/chemistry/pharmacology | 2 | 66.0 |
Receptors, Immunologic/*metabolism | 2 | 1.0 |
Gene Library | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Chromatography, Gel | 2 | 0.0 |